Table 2 Comparisons of HPV-specific geometric mean (GM) memory B cell concentrations at M12 after 1, 2 or 3 doses of HPV vaccine in DoRIS trial (per-protocol cohort1)

From: Memory B-cells elicited by different HPV vaccine regimens in the DoRIS randomised controlled trial

  

1 dose

 

2 doses

 

3 doses

Geometric mean memory B cell ratio (95% CI)

 

N2

GM3 (95% CI)

N2

GM3 (95% CI)

N2

GM3 (95% CI)

1 dose / 2 dose

1 dose / 3 dose

2 dose / 3 dose

     

Month 1 Cervarix®

    

HPV-16

145

0.030 (0.021–0.044)

141

0.039 (0.027–0.056)

138

0.025 (0.017–0.036)

0.78 (0.47–1.29)

1.22 (0.73–2.04)

1.58 (0.94–2.64)

HPV-18

138

0.025 (0.017–0.036)

140

0.026 (0.018–0.037)

133

0.019 (0.013–0.029)

0.97 (0.57–1.64)

1.27 (0.75–2.18)

1.32 (0.77–2.25)

     

Gardasil-9®

    

HPV-16

142

0.045 (0.032 -0.063)

137

0.039 (0.027–0.055)

136

0.054 (0.039–0.075)

1.15 (0.72–1.86)

0.83 (0.51–1.33)

0.72 (0.44–1.16)

HPV-18

133

0.019 (0.013–0.027)

133

0.016 (0.011–0.023)

137

0.025 (0.018–0.037)

1.15 (0.68–1.94)

0.73 (0.44–1.23)

0.64 (0.38–1.07)

     

Month 7 Cervarix®

    

HPV-16

144

0.074 (0.055–0.101)

141

0.588 (0.498–0.694)

140

0.769 (0.655–0.903)

0.13 (0.09–0.17)

0.10 (0.07–0.13)

0.76 (0.56–1.04)

HPV-18

137

0.063 (0.047–0.085)

140

0.359 (0.295–0.438)

135

0.428 (0.356–0.516)

0.18 (0.13–0.24)

0.15 (0.11–0.20)

0.84 (0.61–1.16)

     

Gardasil-9®

    

HPV-16

142

0.080 (0.059–0.109)

139

0.897 (0.774–1.039)

141

0.758 (0.648–0.886)

0.09 (0.07–0.12)

0.11 (0.08–0.14)

1.18 (0.87–1.61)

HPV-18

133

0.050 (0.037–0.068)

134

0.324 (0.265–0.397)

142

0.285 (0.227–0.356)

0.15 (0.11–0.22)

0.18 (0.12–0.25)

1.14 (0.81–1.61)

     

Month 12 Cervarix®

    

HPV-16

136

0.078 (0.060–0.103)

133

0.130 (0.104–0.164)

134

0.183 (0.142–0.236)

0.60 (0.42–0.86)

0.43 (0.30–0.61)

0.71 (0.50–1.02)

HPV-18

130

0.074 (0.056–0.096)

132

0.098 (0.076–0.126)

129

0.148 (0.119–0.185)

0.75 (0.53–1.06)

0.50 (0.35–0.70)

0.66 (0.47–0.94)

     

Gardasil-9®

    

HPV-16

142

0.111 (0.086–0.143)

135

0.185 (0.149–0.231)

133

0.238 (0.201–0.281)

0.60 (0.44–0.81)

0.47 (0.34 –0.64)

0.78 (0.57–1.06)

HPV-18

134

0.074 (0.056–0.096)

130

0.110 (0.088–0.138)

133

0.132 (0.106–0.164)

0.67 (0.48–0.94)

0.56 (0.40–0.78)

0.84 (0.60–1.17)

     

Month 24 Cervarix®

    

HPV-16

145

0.036 (0.024–0.053)

136

0.103 (0.072–0.147)

134

0.114 (0.077–0.167)

0.35 (0.20–0.59)

0.31 (0.18–0.54)

0.91 (0.53–1.56)

HPV-18

138

0.023 (0.015–0.036)

135

0.051 (0.034–0.075)

131

0.065 (0.042–0.100)

0.45 (0.25–0.82)

0.35 (0.20–0.64)

0.78 (0.43–1.42)

     

Gardasil-9®

    

HPV-16

143

0.049 (0.032–0.074)

137

0.113 (0.076–0.167)

136

0.144 (0.099–0.209)

0.43 (0.25–0.75)

0.34 (0.20–0.59)

0.78 (0.45–1.37)

HPV-18

134

0.020 (0.013–0.032)

132

0.045 (0.029–0.070)

137

0.067 (0.044–0.102)

0.45 (0.25–0.84)

0.30 (0.17–0.56)

0.67 (0.36–1.23)

     

Month 36 Cervarix®

    

HPV-16

142

0.013 (0.009–0.018)

140

0.016 (0.011–0.024)

135

0.034 (0.023–0.050)

0.78 (0.46–1.32)

0.37 (0.22–0.63)

0.48 (0.28–0.82)

HPV-18

136

0.011 (0.008–0.017)

139

0.013 (0.009–0.019)

130

0.023 (0.015–0.034)

0.86 (0.50–1.50)

0.50 (0.28–0.87)

0.58 (0.33–1.01)

     

Gardasil-9®

    

HPV-16

137

0.014 (0.010–0.022)

138

0.026 (0.018–0.038)

138

0.040 (0.027–0.058)

0.55 (0.32–0.96)

0.36 (0.21–0.63)

0.66 (0.38–1.13)

HPV-18

129

0.010 (0.006–0.014)

133

0.014 (0.009–0.021)

139

0.024 (0.016–0.036)

0.68 (0.38–1.21)

0.40 (0.23–0.71)

0.59 (0.33–1.03)

  1. 1DoRIS participants who were ELISA antibody negative & DNA negative at baseline (pre-vaccination) for the HPV genotype under analysis. 2Number with detectable HPV-specific memory B cells at Month 36. 3Geometric mean % of HPV-specific circulating memory B cells. Values below the assay limit of quantitation (LLQ) are set to 0.5*LLQ for analysis.
Back to article page